Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/DCR.0000000000001781 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The modified melphalan and busulfan-based regimen combined with maintenance therapy improved the survival of patients with refractory/relapsed AML after allogeneic transplantation: middle-term outcome of a multicenter trial.
Am J Cancer Res
October 2024
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Tianjin 300020, China.
Article Synopsis
- - Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is currently the best curative option for patients with refractory or relapsed acute myeloid leukemia (AML), but long-term survival rates are still not ideal; researchers are working to improve conditioning regimens like the new MCBC (Melphalan, Cladribine, Busulfan, Cyclophosphamide).
- - In a study involving 56 patients treated from July 2020 to January 2022, the 2-year overall survival rate was 60.7% and relapse-free survival rate was 57.1%, with a median follow-up of about 2.3 years.
- - Key findings highlighted that patients
Background: Utilization of autologous adipose tissue transplantation in plastic and orthopedic surgery such as breast reconstruction and intra-articular injection has become an attractive surgical treatment with satisfactory clinical outcomes. Nevertheless, repeated liposuctions necessary to harvest fatty tissue, normally performed with sedation or general anesthesia, may represent a noteworthy concern.
Objectives: The aim of this study was to demonstrate through an in vitro characterization the validity of the surgical option of cryopreserved autologous adipose tissue harvested in a single shot for repeated graft transfer in breast reconstruction without impairment of cell viability and sterility.
Impact of Gambling on the Internet on Middle-Term and Long-Term Recovery from Gambling Disorder: A 2-Year Longitudinal Study.
J Gambl Stud
September 2024
Nantes Université, CHU Nantes, UIC Psychiatrie et Santé Mentale, Nantes, F-44000, France.
Online gamblers are more likely to experience gambling problems. The main objective was to compare the frequency of recovery one (middle-term) and two (long-term) years after treatment initiation, according to the gambling medium (Internet vs. land-based gambling).
View Article and Find Full Text PDFLong-term effects of mepolizumab in patients with severe eosinophilic asthma: a 6-year real-life experience.
Front Pharmacol
August 2024
Department of Clinical Medicine and Surgery, University of Naples "Federico II", Naples, Italy.
Background: Severe eosinophilic asthma (SEA) is often linked to a dysregulation in the Interleukin-(IL)-5 axis. Mepolizumab, a humanized monoclonal antibody, reduces eosinophils by directly binging to IL-5, potentially restoring homeostatic eosinophil biology, with a significant impact on quality of life, acute exacerbations and oral corticosteroids (OCS) elimination in SEA patients. While its short- and middle-term effects are well described, no study has so far investigated its long-lasting effects in SEA patients.
View Article and Find Full Text PDFEffectiveness and Safety of Different Patch Materials for Supravalvar Aortic Stenosis (Middle-Term Outcomes).
Rev Cardiovasc Med
January 2024
Department of Pediatric Cardiac Center, Beijing Anzhen Hospital, Capital Medical University, 100029 Beijing, China.
Background: To determine the effectiveness and safety of different patch materials in the treatment of pediatric patients with congenital supravalvular aortic stenosis (SVAS).
Methods: 218 consecutive SVAS patients (age 14 years) who underwent surgery from Beijing Fuwai and Yunnan Fuwai hospital between 2002 and 2020 were included. Patients were divided into the pericardium patch group (133 (61.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!